InNexus primate study clears way for human trials on non-Hodgkins lymphoma tumors

January 14, 2009

By Flinn Foundation

[Source: Phoenix Business Journal – by Angela Gonzales] – InNexus Biotechnology Inc. has completed a primate study it says confirms the effectinvess and safety of its treatment for non-Hodgkins lymphoma tumors.

The Toronto, Canadian company (TSX:IXS.V), whose business offices are based in Scottsdale, also scheduled a meeting with the U.S. Food and Drug Administration to discuss the design of a clinical study on humans.


For more information click here.